Navigation Links
Cornerstone Therapeutics to Present at BioCentury's 2009 Future Leaders in the Biotech Industry Conference
Date:3/31/2009

CARY, N.C., March 31 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory market, today announced that Craig A. Collard, President and Chief Executive Officer, will be presenting a corporate overview at BioCentury's 16th Annual Future Leaders in the Biotech Industry Conference at 2:00 PM EDT on Thursday, April 2, 2009, at the Millennium Broadway Hotel & Conference Center in New York City.

A live audio and archived webcast of Cornerstone's presentation will be available through the Investor Relations section of the Company's website.

About Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (Nasdaq: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory market. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a late-stage clinical pipeline with five regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory pharmaceutical products, or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force which is focused on the respiratory market; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

    Investor Relations Contacts:
    FD
    Evan Smith/Brian Ritchie
    212-850-5600
    evan.smith@fd.com/brian.ritchie@fd.com

    Media Relations Contact:
    FD
    Robert Stanislaro
    212-850-5600
    robert.stanislaro@fd.com


'/>"/>
SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
2. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
3. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
4. Arno Therapeutics Reports 2008 Year-End Financial Results
5. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
6. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
7. Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics
8. Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
9. Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
10. Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure
11. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... The Blavatnik Family Foundation and ... Finalists of the 2017 Blavatnik Regional Awards for Young Scientists. Established in ... by the New York Academy of Sciences to honor the excellence of outstanding ...
(Date:10/12/2017)... Diego, CA (PRWEB) , ... ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically ... all bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., a ... Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas ... practices and how Proscia improves lab economics and realizes an increase in diagnostic ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
Breaking Biology Technology:
(Date:5/23/2017)... May 23, 2017  Hunova, the first robotic gym for the rehabilitation ... officially launched in Genoa, Italy . The first 30 ... and the USA . The technology was developed and ... by the IIT spin-off Movendo Technology thanks to a 10 million euro ... Release, please click: ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
Breaking Biology News(10 mins):